Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-16
    E.g., 2018-10-16

Archive Search

Pages

249 results
12:42 PM, Oct 05, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Vector copy number declines over time in four Fabry disease patients who received Avrobio gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
3:07 PM, Oct 01, 2018  |  BC Extra | Clinical News

Avrobio falls on data for Fabry gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase...
12:53 PM, Aug 13, 2018  |  BC Extra | Company News

Amicus prices Galafold at $315k per year

Amicus Therapeutics Inc. (NASDAQ:FOLD) said Monday that it will price Galafold migalastat at $315,000 per year and vowed to limit annual price increases of the Fabry disease drug to the rate of inflation. On Friday, FDA...
1:35 PM, Aug 10, 2018  |  BC Extra | Company News

Amicus' Galafold wins accelerated approval from FDA

FDA granted accelerated approval to Galafold migalastat from Amicus Therapeutics Inc. (NASDAQ:FOLD) to treat Fabry disease in adults who have amenable mutations. Amicus said the U.S. approval is the first for a new Fabry disease...
12:15 PM, Jun 22, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

lead candidate AVR-RD-01 to treat Fabry's disease. The therapy comprises stem cells engineered to express alpha galactosidase
9:46 PM, Jun 20, 2018  |  BC Extra | Financial News

Four companies in IPO quintet post first-day gains

lead candidate AVR-RD-01 to treat Fabry's disease. The therapy comprises stem cells engineered to express alpha galactosidase
12:14 PM, Jun 01, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Avrobio proposes $86.3M NASDAQ IPO

slated to enter a Phase II trial mid-year -- comprises stem cells engineered to express alpha galactosidase
3:08 PM, May 25, 2018  |  BC Extra | Financial News

Eidos, Avrobio propose NASDAQ IPOs

slated to enter a Phase II trial mid-year -- comprises stem cells engineered to express alpha galactosidase
8:38 AM, Mar 30, 2018  |  BC Week In Review | Clinical News  |  Regulatory

Japan approvals include Hemlibra, Shingrix Galafold

plans to launch the drug "in the coming months." Galafold, a small molecule stabilizer of alpha galactosidase
3:09 PM, Mar 23, 2018  |  BC Extra | Company News

Japan approvals include Hemlibra, Shingrix, Galafold

plans to launch the drug "in the coming months." Galafold, a small molecule stabilizer of alpha galactosidase

Pages